Non-invasive prenatal testing with CENTOGENE


Maximum certainty - Lowest test failure rate among all NIPT technologies

100% safe for mother & child - Only 9ml of blood from the mother required

Fast & reliable results - Results within 5 business days

Test as early as possible - From the 10th gestational week



Order a Test

  1. NIPT

CentoNIPT® - Expertise you can trust

Illumina VeriSeq™ NIPT Solution*

CENTOGENE offers non-invasive prenatal testing that provides a fast and accurate screen for the most common prenatal chromosomal abnormalities.

CentoNIPT® is performed on a single maternal blood sample and combines the latest NGS technology with the highest quality medical reporting. It provides unparalleled accuracy and detection compared to other non-invasive testing methods – ultrasonography or nuchal translucency testing.

CentoNIPT® has the lowest test failure rate among all NIPT technologies on the market. 

What does CentoNIPT® screen for?

  • Down syndrome (Trisomy 21)
  • Edwards syndrome (Trisomy 18)
  • Patau syndrome (Trisomy 13)

The test also detects abnormalities of the sex chromosomes:

  • Turner syndrome (Monosomy X)
  • Klinefelter syndrome (XXY)
  • Jacobs syndrome (XYY)
  • Triple X syndrome (XXX)

CentoNIPT® is based on Verifi Prenatal Test & VeriSeq™ NIPT solution and offers the lowest number of unnecessary invasive testing

Your experts in non-invasive prenatal diagnostics

The CENTOGENE advantage

We offer a comprehensive package starting with NIPT for most common chromosome aneuploidies to prenatal whole exome / whole genome sequencing. After birth, we offer biomarker testing and our whole genetic test portfolio including specialized genetic analysis for critically ill newborns on ICU.

High sensitivity & specificity

CentoNIPT® combines next generation sequencing with integrated measurement of fetal fraction, even at fetal fraction < 4%. This concludes in the lowest technical failure rate and unnecessary invasive testing as follow-up of NIPT tests available. 

Fast & accurate results

Our optimized workflows provide a full clinical diagnostic report within five business days from high-quality, validated results. 

Notation: *Sample Preparation and analysis software are CE-IVD marked

Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision.